Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

319
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
319
Positron Emission Tomography01:29

Positron Emission Tomography

6.5K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
6.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial.

Lancet (London, England)·2026
Same author

CORSA study finds spike-specific blunted immune responses in lymphoma patients after SARS-CoV-2 vaccine.

Frontiers in immunology·2026
Same author

Correction: TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a comprehensive overview of targeted approaches.

Frontiers in oncology·2026
Same author

Prostate-Specific Membrane Antigen (PSMA): A Potential Theranostic Biomarker in Breast Cancer.

Biomedicines·2026
Same author

Underrated, Unvaccinated, Untreated: A Multinational Registry Analysis of Human Metapneumovirus in Hematological Malignancy, Insights From EPICOVIDEHA/EPIRESEHA Registry.

Open forum infectious diseases·2026
Same author

PSMA for HCC: a new frontier in precision medicine for liver cancer?

Cancer treatment and research communications·2026

Related Experiment Video

Updated: Nov 17, 2025

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.0K

PET/CT in Multiple Myeloma: Beyond FDG.

Federica Matteucci1, Giovanni Paganelli1, Giovanni Martinelli2

  • 1Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo studio e la cura dei tumori (IRST) IRCCS, Meldola, Italy.

Frontiers in Oncology
|February 11, 2021
PubMed
Summary
This summary is machine-generated.

New PET/CT imaging tracers beyond 18F-FDG show promise for diagnosing multiple myeloma (MM). These non-FDG tracers offer improved accuracy by overcoming limitations of physiological uptake in bone marrow and brain.

Keywords:
18F-fluorodeoxyglucose-positron emission tomography/computed tomographyFDG-PET/CTcholine positron emission tomography/computed tomographymethionine positron emission tomography/computed tomographymultiple myelomamyelomanew tracers

More Related Videos

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

19.0K
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.3K

Related Experiment Videos

Last Updated: Nov 17, 2025

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.0K
Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

19.0K
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.3K

Area of Science:

  • Nuclear Medicine
  • Oncology
  • Radiochemistry

Background:

  • Positron Emission Tomography/Computed Tomography (PET/CT) is crucial for multiple myeloma (MM) diagnosis, staging, and treatment response assessment.
  • 18F-FDG PET/CT, a common imaging method, offers high sensitivity (80-100%) but faces limitations due to physiological uptake in bone marrow and brain.
  • These limitations necessitate exploring alternative PET tracers for more effective MM management.

Purpose of the Study:

  • To review the characteristics and diagnostic accuracy of non-18F-FDG PET tracers in managing patients with multiple myeloma.
  • To evaluate the potential of novel radiopharmaceuticals in overcoming the limitations of 18F-FDG in MM imaging.
  • To highlight tracers targeting protein metabolism, plasma membrane synthesis, and myeloma-specific receptors.

Main Methods:

  • Literature review of studies evaluating non-18F-FDG PET tracers for multiple myeloma.
  • Analysis of tracers such as those based on choline and methionine, which assess protein metabolism.
  • Inclusion of studies on innovative radiopharmaceuticals targeting myeloma cell receptors, including chemokine receptors.

Main Results:

  • Non-18F-FDG tracers offer potential advantages by circumventing the physiological uptake issues associated with 18F-FDG.
  • Tracers targeting protein metabolism (e.g., choline, methionine) and specific receptors show promise in MM detection and characterization.
  • The effectiveness of these alternative tracers in improving diagnostic accuracy and patient stratification requires further investigation.

Conclusions:

  • Non-18F-FDG PET tracers represent a valuable area of research for improving multiple myeloma imaging.
  • These alternative radiopharmaceuticals may offer enhanced specificity and overcome the limitations of 18F-FDG, leading to better patient management.
  • Further studies are warranted to establish the clinical utility and optimal application of non-18F-FDG tracers in multiple myeloma.